[1]
|
Zlokarnik, G., Grootenhuis, P.D. and Watson, J.B. (2005) High throughput P450 inhibition screens in early drug discovery. Drug Discovery Today, 10, 1443-1450.
doi:10.1016/S1359-6446(05)03580-4
|
[2]
|
Bell, L., et al. (2008) Evaluation of fluorescenceand mass spectrometry-based CYP inhibition assays for use in drug discovery. Journal of Biomolecular Screening, 13, 343-353. doi:10.1177/1087057108317480
|
[3]
|
McMasters, D.R., et al. (2007) Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules. Journal of Medicinal Chemistry, 50, 3205-3213. doi:10.1021/jm0700060
|
[4]
|
Rogge, M.C. and Taft, D.R. (2010) Preclinical drug development. 2nd Edition, D.A.T.P. Sciences, 187, Informa Healthcare USA, Inc., New York.
|
[5]
|
Krippendorff, B.F., et al. (2007) Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery. Journal of Biomolecular Screening, 12, 92-99.
doi:10.1177/1087057106295897
|
[6]
|
Crespi, C.L., Miller, V.P. and Penman, B.W. (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analytical Biochemistry, 248, 188-190. doi:10.1006/abio.1997.2145
|
[7]
|
Di, L., et al. (2007) Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. International Journal of Pharmaceutics, 335, 1-11.
doi:10.1016/j.ijpharm.2006.10.039
|
[8]
|
Cohen, L.H., et al. (2003) In vitro drug interactions of cytochrome p450: An evaluation of fluorogenic to conventional substrates. Drug Metabolism and Disposition, 31, 1005-1015. doi:10.1124/dmd.31.8.1005
|
[9]
|
Di, L. and Kerns, E.H. (2003) Profiling drug-like properties in discovery research. Current Opinion in Chemical Biology, 7, 402-408. doi:10.1016/S1367-5931(03)00055-3
|
[10]
|
Gibbs, M.A., et al. (1999) Inhibition of cytochrome P450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metabolism and Disposition, 27, 180187.
|
[11]
|
Lipinski, C.A., et al. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46, 3-26.
doi:10.1016/S0169-409X(00)00129-0
|
[12]
|
Bergstrom, C.A., et al. (2002) Experimental and computational screening models for prediction of aqueous drug solubility. Pharmaceutical Research, 19, 182-188.
doi:10.1023/A:1014224900524
|
[13]
|
Lipinski, C.A. (2000) Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods, 44, 235249. doi:10.1016/S1056-8719(00)00107-6
|
[14]
|
Stresser, D.M., et al. (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metabolism and Disposition, 28, 1440-1448.
|
[15]
|
Wang, R.W., et al. (2000) Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition, 28, 360-366.
|
[16]
|
Korzekwa, K.R., et al. (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 41374147. doi:10.1021/bi9715627
|
[17]
|
Kenworthy, K.E., et al. (1999) CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology, 48, 716-727.
doi:10.1046/j.1365-2125.1999.00073.x
|
[18]
|
Galetin, A., et al. (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. Journal of Pharmacology and Experimental Therapeutics, 314, 180-190. doi:10.1124/jpet.104.082826
|
[19]
|
Lin, J.H. (2000) Sense and nonsense in the prediction of drug-drug interactions. Current Drug Metabolism, 1, 305331. doi:10.2174/1389200003338947
|
[20]
|
Walsky, R.L. and Obach, R.S. (2004) Validated assays for human cyto-chrome P450 activities. Drug Metabolism and Disposition, 32, 647-660. doi:10.1124/dmd.32.6.647
|
[21]
|
Margolis, J.M. and Obach, R.S. (2003) Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metabolism and Disposition, 31, 606-611.
doi:10.1124/dmd.31.5.606
|
[22]
|
Chauret, N., et al. (1999) Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe. Analytical Biochemistry, 276, 215-226.
doi:10.1006/abio.1999.4348
|
[23]
|
Pérez, J., Sánchez, M. and Peláez, F. (2004) Suitability of DMSO as a solvent for the compounds to be tested in cytochrome 3A4, 2C9 and 2D6 P450 isoforms inhibition assays. Annual Meeting of Society of Bimolecular Screening, Madrid.
|
[24]
|
Di Marco, A., et al. (2005) Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metabolism and Disposition, 33, 349-358. doi:10.1124/dmd.104.002873
|
[25]
|
Fowler, S.M., et al. (2002) CYP3A4 active site volume modification by mutagenesis of leucine 211. Drug Metabolism and Disposition, 30, 452-456.
doi:10.1124/dmd.30.4.452
|
[26]
|
Kroemer, H.K., et al. (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Archives of Pharmacology, 348, 332-337. doi:10.1007/BF00169164
|
[27]
|
Busse, D., et al. (1995) Cytochromes of the P450 2C sub-family are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Archives of Pharmacology, 353, 116-121.
doi:10.1007/BF00168924
|
[28]
|
Venkatakrishnan, K., von Moltke, L.L. and Greenblatt, D.J. (1999) CYP2C9 is a principal low-affinity phenacetin O-deethylase: Fluvoxamine is not a specific CYP1A2 inhibitor. Drug Metabolism and Disposition, 27, 15191522.
|
[29]
|
Tracy, T.S., et al. (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. British Journal of Clinical Pharmacology, 47, 545-552.
doi:10.1046/j.1365-2125.1999.00923.x
|
[30]
|
Wang, Y.H., Jones, D.R. and Hall, S.D. (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metabolism and Disposition, 32, 259-266. doi:10.1124/dmd.32.2.259
|
[31]
|
Racha, J.K., et al. (2003) Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metabolism and Pharmacokinetics, 18, 128-138.
doi:10.2133/dmpk.18.128
|
[32]
|
Rodrigues, A.D. (1999) Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology, 57, 465-480.
|